SURMOUNT-1 Trial: Tirzepatide Achieves Up to 22.5% Weight Loss in Adults Without Diabetes

The SURMOUNT-1 Trial: Redefining What's Possible in Obesity Medicine

The SURMOUNT-1 trial represents a watershed moment in the treatment of obesity. Published in the New England Journal of Medicine in July 2022 by Jastreboff et al., this double-blind, randomized, placebo-controlled Phase 3 trial demonstrated that once-weekly tirzepatide — a first-in-class dual GIP and GLP-1 receptor agonist — produced weight loss of a magnitude never before seen with any pharmaceutical agent [1].

Study Design and Population

SURMOUNT-1 enrolled 2,539 adults across 119 sites in 9 countries. Eligibility required a body mass index (BMI) of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity (hypertension, dyslipidemia, or obstructive sleep apnea). Crucially, participants did not have type 2 diabetes, isolating the weight loss effects from glucose-lowering confounders.

Participants were randomized 1:1:1:1 to receive tirzepatide 5 mg, 10 mg, or 15 mg, or placebo via once-weekly subcutaneous injection for 72 weeks. All groups received lifestyle intervention counseling (500 kcal/day deficit and ≥150 minutes/week of physical activity).

The dose escalation schedule was designed to improve tolerability: all tirzepatide groups started at 2.5 mg weekly and escalated by 2.5 mg every 4 weeks until reaching their assigned dose.

Primary Efficacy Results

The results were unprecedented across all three tirzepatide doses:

Mean Body Weight Change at 72 Weeks:

• Tirzepatide 5 mg: -15.0% (approximately -16.1 kg)
• Tirzepatide 10 mg: -19.5% (approximately -22.2 kg)
• Tirzepatide 15 mg: -22.5% (approximately -23.6 kg)
• Placebo: -3.1% (approximately -2.4 kg)

Categorical Weight Loss Thresholds (15 mg dose):

• ≥5% weight loss: 91% of tirzepatide patients vs. 35% placebo
• ≥10% weight loss: 81% vs. 14%
• ≥15% weight loss: 68% vs. 6%
• ≥20% weight loss: 57% vs. 3%
• ≥25% weight loss: 36% vs. 1%

The 22.5% mean weight loss with the 15 mg dose was approximately 50% greater than the 14.9% achieved by semaglutide 2.4 mg in the STEP 1 trial, establishing tirzepatide as the new benchmark in pharmacological weight management [1].

The Dual Agonist Mechanism

Tirzepatide's superior weight loss is attributed to its unique dual mechanism:

GLP-1 Receptor Agonism:

• Reduces appetite through hypothalamic signaling
• Slows gastric emptying, promoting satiety
• Enhances insulin secretion in a glucose-dependent manner

GIP Receptor Agonism:

• Promotes fat oxidation and energy expenditure
• Enhances the weight-lowering effects of GLP-1 signaling
• May improve adipose tissue metabolism and reduce fat mass preferentially

This dual action creates a synergistic effect that exceeds what either pathway achieves alone, explaining why tirzepatide produces greater weight loss than pure GLP-1 receptor agonists like semaglutide [2].

Cardiometabolic Improvements

Beyond weight loss, SURMOUNT-1 demonstrated comprehensive cardiometabolic benefits:

• Waist circumference: -14.5 cm (15 mg) vs. -3.4 cm (placebo)
• Systolic blood pressure: -7.2 mmHg vs. -1.0 mmHg
• Triglycerides: -25.6% vs. +3.0%
• HDL cholesterol: +7.0% vs. +0.6%
• Fasting insulin: -55.0% vs. -3.5%
• HbA1c: -0.5% vs. -0.1% (in non-diabetic participants)
• C-reactive protein: Significant reduction indicating decreased systemic inflammation

These improvements suggest that tirzepatide addresses the metabolic syndrome broadly, not just body weight [1].

Safety Profile

The safety data from SURMOUNT-1 were consistent with the GLP-1 receptor agonist class:

Gastrointestinal Adverse Events (15 mg):

• Nausea: 31.0% vs. 9.5% (placebo)
• Diarrhea: 23.0% vs. 7.3%
• Vomiting: 12.8% vs. 2.8%
• Constipation: 11.7% vs. 5.0%

Most GI events were mild to moderate and occurred during the dose-escalation phase. Importantly, the gradual 4-week dose escalation helped mitigate the severity of these side effects.

Discontinuation rates due to adverse events were 4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg) vs. 2.6% (placebo).

Serious adverse events occurred at similar rates across groups (5-7%), with no new safety signals identified. Gallbladder events were slightly more common with tirzepatide, consistent with rapid weight loss [1].

Comparison to Bariatric Surgery

The 22.5% weight loss with tirzepatide 15 mg approaches the range typically achieved with certain bariatric procedures:

While bariatric surgery still produces greater average weight loss, tirzepatide offers a non-surgical alternative that achieves results in the same range as less invasive surgical procedures [1].

Impact on Obesity Treatment

SURMOUNT-1 fundamentally changed the obesity treatment landscape:

1. New efficacy standard: Established 20%+ weight loss as achievable with pharmacotherapy
2. FDA approval: Led to Zepbound (tirzepatide) approval for chronic weight management in November 2023
3. Paradigm shift: Demonstrated that dual-agonist approaches can exceed single-target therapies
4. Access expansion: Provided an alternative to bariatric surgery for patients who cannot or prefer not to undergo surgery

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387(3):205-216. PubMed: 35658024

2. Coskun T, Sloop KW, Loghin C, et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept." Molecular Metabolism. 2018;18:3-14. PubMed: 30473097

3. Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." New England Journal of Medicine. 2021;385(6):503-515. PubMed: 34170647